drugset / Trial / NCT03411967
Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC
Phase 2
Unknown
20 enrolled
Zigong No.1 Peoples Hospital
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
In order to explore a new treatment strategy for patients with failed NSCLC platinum-containing double-drug therapy, this study was to investigate the clinical efficacy of apatinib in combination with docetaxel for patients with advanced NSCLC after failure of platinum-based regime
Timeline
- Start
- 2018-02-01
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |